Provided by Tiger Fintech (Singapore) Pte. Ltd.

Relmada Therapeutics, Inc.

0.2927
+0.02097.69%
Post-market: 0.29270.00000.00%19:08 EDT
Volume:1.05M
Turnover:302.48K
Market Cap:8.83M
PE:-0.10
High:0.3004
Open:0.2800
Low:0.2726
Close:0.2718
Loading ...

Company Profile

Company Name:
Relmada Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
20
Office Location:
2222 Ponce de Leon Boulevard,Floor 3,Coral Gables,Florida,United States
Zip Code:
33134
Fax:
- -
Introduction:
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Directors

Name
Position
Charles J. Casamento
Chairman of the Board and Director
Sergio Traversa
Chief Executive Officer and Director
Eric Schmidt
Director
John Glasspool
Director
Paul Kelly
Director

Shareholders

Name
Position
Sergio Traversa
Chief Executive Officer and Director
Maged Shenouda
Chief Financial Officer
Charles Ence
Chief Accounting and Compliance Officer
Charles J. Casamento
Chairman of the Board and Director
Marco Pappagollo
Acting Chief Medical Officer
Paolo Manfredi
Acting Chief Scientific Officer